CA-LASERFICHE
28.11.2023 16:01:35 CET | Business Wire | Press release
New research by Medical Group Management Association (MGMA) and Laserfiche — the leading SaaS provider of intelligent content management and business process automation — reveals that most healthcare organizations’ top priorities when considering integrative technologies are the elimination of manual work, mitigation of clinician/worker burnout and time savings.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231128977000/en/
Discover the opportunities and challenges for medical practice leaders in evaluating their platforms for workflow, electronic forms, document and records management and more. (Graphic: Business Wire)
“The healthcare industry has been disrupted by the growth of virtual visits, expectations for more personal, faster access to patients’ clinical results and care, plus the rise of AI,” said Grace Nam, strategic solutions manager, healthcare, at Laserfiche. “These trends have created a burgeoning challenge of managing, processing and leveraging an inundation of data that require cross-functional collaboration, and often include external organizations like labs and other physicians.”
The study surveyed medical practice administrators, physicians, billing and coding leaders and health information technology (HIT) workers for their views on electronic health records (EHR) or practice management (PM) systems, business automation and more. According to the report, most healthcare organizations are not looking to make a switch to a new EHR or PM system and nearly 80% of respondents rated their current EHR system as “very good” or “good.” However, when it came time to rate EHR systems’ individual attributes, those ratings dropped. Only half of respondents rated their EHR systems “very good” or “good” at saving time; 47% said they were very good or good at saving money; and only 40% said they were very good or good at mitigating clinician/worker burnout.
“Time-strapped organizations need integrated technologies to extract value from data without adding to the long list of manual tasks for already overwhelmed employees,” Nam added. “Investments in systems that enable business process automation while facilitating information governance are critical to healthcare organizations’ ability to leverage data and retain employees while providing a modern patient experience. Supporting the back office — including medical billing and coding, and working with third-party insurance companies — to boost speed and accuracy will be critical for on-time payments that impact revenue.”
“The business of healthcare and its future are tied directly to the ability to manage and make decisions based on data to support high-quality patient care,” the report states. “As the amount of data generated in healthcare grows about 47% a year, the need to manage the growing volumes of records in a secure, compliant fashion is unmistakable.”
To download a copy of the Intelligent Automation in Healthcare report, visit https://info.laserfiche.com/resource/intelligent-automation-healthcare.
To learn more about Laserfiche solutions for the healthcare industry, visit laserfiche.com/solutions/healthcare.
About Laserfiche
Laserfiche is the leading SaaS provider of intelligent content management and business process automation. Through workflows, e-forms, document management, integrations and analytics, the Laserfiche® platform centralizes information, structures clinical data and streamlines back-office processes so that healthcare professionals can focus on providing the highest standard of patient care.
For over 30 years, Laserfiche has served organizations in the healthcare industry as a trusted system for document and records management, enabling medical professionals to quickly retrieve records when needed, with robust security and compliance tools to support HIPAA compliance and patient confidentiality. By streamlining paperwork, information and data using digital forms and automated workflows, Laserfiche allows administration, clinicians and physicians to eliminate repetitive manual tasks, gain visibility into operations, support a holistic approach to patient care and focus on improving patient outcomes. Prebuilt solutions and integrations with industry-specific and common business applications further extend organizations’ digital transformation initiatives.
Today, Laserfiche’s cloud-first approach incorporates innovations in machine learning and AI, supporting healthcare organizations in empowering staff, streamlining the patient experience, supporting HIPAA compliance and providing the best possible patient experience.
Learn more at laserfiche.com/solutions/healthcare.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231128977000/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
